Trial Profile
A Double-blind, Randomized, Placebo-controlled Phase II Pilot Trial Investigating Efficacy, Safety and Feasibility of 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition by AZD4017 to Improve Skin Function and Wound Healing in Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs AZD 4017 (Primary)
- Indications Chronic wounds; Diabetic foot ulcer
- Focus First in man; Proof of concept; Therapeutic Use
- Acronyms GC-SHealD
- 28 Feb 2022 Results published in the European Journal of Endocrinology
- 21 Mar 2019 Status changed from recruiting to completed.
- 11 Oct 2018 Planned End Date changed from 30 Apr 2019 to 1 Apr 2019.